Kaniz Afroz Tanni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kaniz Afroz Tanni has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jingjing Qian
Auburn University Harrison College of Pharmacy, Auburn, AL
5 shared publications - Bang Truong
Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, USA
3 shared publications Ammarin Thakkinstian
Affiliations Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Mahidol University Health Technology Assessment Graduate Program, Bangkok, Thailand
1 shared publication- Brandon S. Johnson
Spencer Cancer Center, East Alabama Medical Center, Opelika, AL 36801, USA
1 shared publication Mohammad Shahriar
1 shared publicationMukdarut Bangpan
Affiliation The Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre), Social Research Institute, University College London, London, United Kingdom
1 shared publication
Latest Publications
- 10 February 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (3) , 709-719
Comparative safety of generic versus brand calcineurin inhibitors in solid organ transplant patients: A systematic review and meta-analysis
- 10 February 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (3) , 709-719
Comparative safety of generic versus brand calcineurin inhibitors in solid organ transplant patients: A systematic review and meta-analysis
- Open Access
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0269009
Methodological approaches for assessing certainty of the evidence in umbrella reviews: A scoping review
Introduction: The number of umbrella reviews (URs) that compiled systematic reviews and meta-analysis (SR-MAs) has increased dramatically over recent years. No formal guidance for assessing the certainty of evidence in URs of meta-analyses exists nowadays. URs of non-interventional studies help establish evidence linking exposure to certain health outcomes in a population. This study aims to identify and describe the methodological approaches for assessing the certainty of the evidence in published URs of non-interventions. Methods: We searched from 3 databases including PubMed, Embase, and The Cochrane Library from May 2010 to September 2021. We included URs that included SR-MAs of studies with non-interventions. Two independent reviewers screened and extracted data. We compared URs characteristics stratified by publication year, journal ranking, journal impact factor using Chi-square test. Results: Ninety-nine URs have been included. Most were SR-MAs of observational studies evaluating association of non-modifiable risk factors with some outcomes. Only half (56.6%) of the included URs assessed the certainty of the evidence. The most frequently used criteria is credibility assessment (80.4%), followed by GRADE approach (14.3%). URs published in journals with higher journal impact factor assessed certainty of evidence than URs published in lower impact group (77.1 versus 37.2% respectively, p < 0.05). However, criteria for credibility assessment used in four of the seven URs that were published in top ranking journals were slightly varied. Conclusions: Half of URs of MAs of non-interventional studies have assessed the certainty of the evidence, in which criteria for credibility assessment was the commonly used method. Guidance and standards are required to ensure the methodological rigor and consistency of certainty of evidence assessment for URs.
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0269009
Open AccessMethodological approaches for assessing certainty of the evidence in umbrella reviews: A scoping review
Introduction: The number of umbrella reviews (URs) that compiled systematic reviews and meta-analysis (SR-MAs) has increased dramatically over recent years. No formal guidance for assessing the certainty of evidence in URs of meta-analyses exists nowadays. URs of non-interventional studies help establish evidence linking exposure to certain health outcomes in a population. This study aims to identify and describe the methodological approaches for assessing the certainty of the evidence in published URs of non-interventions. Methods: We searched from 3 databases including PubMed, Embase, and The Cochrane Library from May 2010 to September 2021. We included URs that included SR-MAs of studies with non-interventions. Two independent reviewers screened and extracted data. We compared URs characteristics stratified by publication year, journal ranking, journal impact factor using Chi-square test. Results: Ninety-nine URs have been included. Most were SR-MAs of observational studies evaluating association of non-modifiable risk factors with some outcomes. Only half (56.6%) of the included URs assessed the certainty of the evidence. The most frequently used criteria is credibility assessment (80.4%), followed by GRADE approach (14.3%). URs published in journals with higher journal impact factor assessed certainty of evidence than URs published in lower impact group (77.1 versus 37.2% respectively, p < 0.05). However, criteria for credibility assessment used in four of the seven URs that were published in top ranking journals were slightly varied. Conclusions: Half of URs of MAs of non-interventional studies have assessed the certainty of the evidence, in which criteria for credibility assessment was the commonly used method. Guidance and standards are required to ensure the methodological rigor and consistency of certainty of evidence assessment for URs.
- 1 November 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (11) , 1408-1413
Trends in gender and race/ethnicity of PharmD students and faculty in US pharmacy schools
- 1 November 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (11) , 1408-1413
Trends in gender and race/ethnicity of PharmD students and faculty in US pharmacy schools
- 1 July 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 163, 103375
Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis
- 1 July 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 163, 103375
Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis
- 16 April 2021
- Published by Springer Nature in BioDrugs
- Vol. 35 (3) , 375-377
Author’s Reply to Joerg Putzke et al. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
- 16 April 2021
- Published by Springer Nature in BioDrugs
- Vol. 35 (3) , 375-377
Author’s Reply to Joerg Putzke et al. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
- 13 January 2021
- Published by Springer Nature in BioDrugs
- Vol. 35 (2) , 239-254
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Background Since the approval and availability of the first biosimilar in 2015 in the United States (US), evidence regarding the post-marketing safety of cancer supportive care biosimilars remains limited. Objective The aim was to explore the adverse event (AE) reporting patterns and detect disproportionate reporting signals for cancer supportive care biosimilars in the US compared to their originator biologics. Methods The US Food and Drug Administration Adverse Event Reporting System database (January 1, 2004–March 31, 2020) was used to identify AE reports for filgrastim, pegfilgrastim, and epoetin alpha by type of product (originator biologics vs. biosimilars) and report characteristics. Plots of AE reports against years were used to reveal the reporting patterns. Disproportionality analyses using reporting odds ratios (RORs) were conducted to detect differences in serious and specific AEs between studied drugs and all other drugs. Breslow–Day tests were used to determine homogeneity between the originator biologic–biosimilar pair RORs for the same AE. Results Total numbers of AEs for all studied biosimilars increased after marketing. More AE reports were from female patients for all of the studied drugs. More AEs for originator biologics and filgrastim biosimilar were reported by health professionals, while the highest proportion of reports came from consumers for pegfilgrastim and epoetin alpha biosimilars (29% and 44.1%, respectively). Signals of disproportionate reporting in serious AEs were detected for a pegfilgrastim biosimilar (Fulphila®) compared to its originator biologic. Conclusion Our findings support the similarity in the signals of disproportionate reporting between cancer supportive care originator biologics and biosimilars, except for Fulphila®.
- 13 January 2021
- Published by Springer Nature in BioDrugs
- Vol. 35 (2) , 239-254
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Background Since the approval and availability of the first biosimilar in 2015 in the United States (US), evidence regarding the post-marketing safety of cancer supportive care biosimilars remains limited. Objective The aim was to explore the adverse event (AE) reporting patterns and detect disproportionate reporting signals for cancer supportive care biosimilars in the US compared to their originator biologics. Methods The US Food and Drug Administration Adverse Event Reporting System database (January 1, 2004–March 31, 2020) was used to identify AE reports for filgrastim, pegfilgrastim, and epoetin alpha by type of product (originator biologics vs. biosimilars) and report characteristics. Plots of AE reports against years were used to reveal the reporting patterns. Disproportionality analyses using reporting odds ratios (RORs) were conducted to detect differences in serious and specific AEs between studied drugs and all other drugs. Breslow–Day tests were used to determine homogeneity between the originator biologic–biosimilar pair RORs for the same AE. Results Total numbers of AEs for all studied biosimilars increased after marketing. More AE reports were from female patients for all of the studied drugs. More AEs for originator biologics and filgrastim biosimilar were reported by health professionals, while the highest proportion of reports came from consumers for pegfilgrastim and epoetin alpha biosimilars (29% and 44.1%, respectively). Signals of disproportionate reporting in serious AEs were detected for a pegfilgrastim biosimilar (Fulphila®) compared to its originator biologic. Conclusion Our findings support the similarity in the signals of disproportionate reporting between cancer supportive care originator biologics and biosimilars, except for Fulphila®.
- Open Access
- 17 August 2017
- Published by Asian Pacific Journal of Tropical Medicine Press in Journal of Coastal Life Medicine
- p. 360-364
Phytochemical screening, antibacterial and anthelmintic activities of leaf and seed extracts of Coix lacryma-jobi L.
- 17 August 2017
- Published by Asian Pacific Journal of Tropical Medicine Press in Journal of Coastal Life Medicine
- p. 360-364
Open AccessPhytochemical screening, antibacterial and anthelmintic activities of leaf and seed extracts of Coix lacryma-jobi L.